Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest glycopyrrolate Stories

2013-09-03 08:27:37

DORVAL, QC, Sept. 3, 2013 /CNW/ - Ontario patients suffering from chronic obstructive pulmonary disease (COPD) now have access to SEEBRI* BREEZHALER* (glycopyrronium bromide) 50 mcg with its listing as a General Benefit on the Ontario Drug Benefit (ODB) Formulary. SEEBRI* BREEZHALER* is available in pharmacies province-wide. SEEBRI* BREEZHALER* is a long-acting anticholinergic (LAAC) indicated for long-term, once-daily maintenance bronchodilator treatment in patients with COPD,...

2013-08-16 04:20:20

OXFORD, England, August 16, 2013 /PRNewswire/ -- PSX1002 is a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA) Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has completed all patient dosing sessions and follow-up procedures in its Phase 2 clinical study with PSX1002. PSX1002 is a novel,...

2013-05-22 04:21:01

OXFORD, England, May 22, 2013 /PRNewswire/ -- First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung...

2013-05-20 12:24:37

Phase III Clinical Data Indicate That Indacaterol/Glycopyrronium Has Advantages Over Current Therapies for Efficacy, According to a New Report from Decision Resources BURLINGTON, Mass., May 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European pulmonologists agree that therapies offering a greater effect on quality of life is among the areas of highest unmet...

2012-11-07 04:23:10

TOKYO, November 7, 2012 /PRNewswire/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) confirms the information released today by Novartis Pharma K.K. that it has submitted an application for the registration of QVA149, an investigational fixed dose combination of two long-acting inhaled bronchodilators (indacaterol maleate and glycopyrronium bromide), as a once-daily treatment for chronic obstructive pulmonary disease (COPD) in Japan. CEO of Sosei, Shinichi...

2012-09-02 18:22:46

VIENNA, Sept. 3, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. today presented positive efficacy and safety results from the GOLDEN-1 study - a Phase 2b study evaluating EP-101 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) - at the annual meeting of the European Respiratory Society in Vienna, Austria. As previously announced, EP-101 demonstrated a rapid onset, dose-related, statistically significant improvement in lung function compared to placebo....

2012-08-27 02:25:10

GREENSBORO, N.C., Aug. 27, 2012 /PRNewswire/ -- Merz, Inc. (U.S. affiliate of Merz Pharma Group) today announced the acquisition of CUVPOSA(®) (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy. Cerebral palsy (CP) is a lifelong condition that encompasses a group of non-progressive, neurological disorders affecting body movement and muscle coordination. According to previous estimates from a study reported by...

2012-01-25 07:00:00

FLORHAM PARK, N.J., Jan. 25, 2012 /PRNewswire/ -- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced results from two studies published online today in the journal Therapeutics and Clinical Risk Management: the first study, a randomized, double-blind, placebo-controlled phase III trial, showed that children ages 3-16 with problem drooling due to neurologic conditions demonstrated a significantly better response to CUVPOSA® (glycopyrrolate)...

2011-10-21 14:27:00

CORAL SPRINGS, Fla., Oct. 21, 2011 /PRNewswire/ -- Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and 2 mg, the generic version of Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, Inc. Glycopyrrolate tablets are intended for use as adjunctive therapy in the treatment of peptic ulcers. "We're up to our third approval this year," said...

2011-09-26 07:00:00

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive results from a Phase 2a study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a large and growing disease characterized by significant unmet clinical needs, at the annual meeting of the European Respiratory...